Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor.

Abstract

Future aerosol therapy with rSLPI will be most beneficial for well ventilated lung tissue that needs protection against neutrophil derived elastase. It may be more difficult to neutralise the burden of elastase in poorly ventilated, highly inflamed areas as are seen in cystic fibrosis.